Press Releases

Companies press releases

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Ingelheim, Germany, and Princeton, New Jersey, USA, August 18, 2025 – Boehringer Ingelheim and Palatin Technologies, Inc., (OTCQB: PTNTD), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced a global research collaboration and licensing agreement aiming to develop an innovative therapy for retinal diseases. […]

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases Read More »

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity

Jul 15, 2025, 07:30 ET Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling toxicology program ongoing IND submission planned for 4Q2025; Clinical data expected in 1H2026 PRINCETON, N.J., July 15, 2025 /PRNewswire/ — Palatin Technologies,

Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity Read More »

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 14, 2025, 07:30 ET Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today – May 14, 2025, at 11:00 AM EST CRANBURY, N.J., May 14, 2025 /PRNewswire/ — Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update Read More »

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

May 09, 2025, 07:30 ET Findings highlight PL9654 and PL9655’s potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and function Topical and systemic administration options enable potential for earlier intervention than current therapies Results support the continued development of

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 Read More »

Palatin Technologies Announces Closing of Reduced Public Offering

May 08, 2025, 22:19 ET Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ — Palatin Technologies, Inc. (OTC PINK: PTNT) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced

Palatin Technologies Announces Closing of Reduced Public Offering Read More »

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

May 08, 2025, 16:39 ET Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. 6 of 13 symptom endpoints reached statistical significance (p<0.05). This level of symptom clearing has not been demonstrated by any

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 Read More »

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 07, 2025, 20:26 ET The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J., May 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC (“NYSE

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice Read More »

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 07, 2025, 08:15 ET Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications planned for Q4 2025; clinical data expected H1 2026 Phase 1 SAD/MAD studies to include patients with hypothalamic obesity Ocular asset collaborations expected in Q2 and Q3

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice Read More »

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 07, 2025, 08:00 ET $11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J., May 7, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of

Palatin Technologies Announces Pricing of up to $23 Million Public Offering Read More »

Scroll to Top